News | April 27, 2009

Varian to Show Brachytherapy, IMRT, SBRT at AUA Meeting

April 27, 2009 - Varian Medical Systems is showcasing the its full spectrum of prostate cancer treatment technologies, including brachytherapy, IMRT and SBRT, at the American Urological Association (AUA) Meeting at McCormick Place in Chicago from April 25-30.

"At the AUA meeting, we'll be exhibiting our latest solutions for high-dose-rate brachytherapy, planning for low-dose brachytherapy with permanent seed implants, 3D conformal radiotherapy, intensity-modulated radiotherapy (IMRT), and stereotactic body radiotherapy (SBRT)," said Calvin Huntzinger, MS, senior director, Varian Surgical Sciences. Each is a different approach to targeting prostate tumors with radiation.

Varian recently produced a clinical perspectives paper entitled “Early-stage prostate cancer treatment alternatives,” highlighting research that contrasts these and other approaches to prostate cancer treatment.

Varian will be showcasing the following radiotherapy solutions at the AUA meeting:

- The VariSource and GammaMed lines of HDR brachytherapy afterloaders, a computer-controlled device for guiding a needle or catheter as it places a radiation source directly into a tumor and holds it there for a prescribed period of time while the dose is delivered.
- VariSeed brachytherapy treatment planning software, which facilitates the permanent implantation of tiny radioactive seeds, each the size of a grain of rice, directly into the prostate.

Also showcased will be the Novalis Tx platform for image-guided radiotherapy and radiosurgery, a suite of tools made by Varian and BrainLAB for delivering external beam radiotherapies, including 3D conformal, IMRT, RapidArc radiotherapy and SBRT.

Novalis Tx can also deliver RapidArc radiotherapy, making it possible to complete an IMRT or SBRT treatment very quickly by dosing the entire tumor volume with a single rotation of the treatment machine around the patient.

The American Urological Association Meeting will take place at McCormick Place in Chicago, April 25-30.

For more information: www.varian.com

Related Content

New Data Demonstrates Safety Profile of GammaTile Therapy for Various Brain Tumors
News | Brachytherapy Systems | June 18, 2019
GT Medical Technologies Inc. announced the presentation of clinical data from a prospective study of GammaTile Therapy...
Black Men Less Likely to Adopt Active Surveillance for Low-Risk Prostate Cancer
News | Prostate Cancer | June 17, 2019
A new study reveals black men are less likely than white men to adopt an active surveillance strategy for their...
University Medical Center Groningen Performs First Automatic Log-based Proton Therapy Patient QA
News | Proton Therapy | June 14, 2019
IBA announced the physics team of University Medical Center Groningen (UMCG) in the Netherlands has developed and...
ASTRO Applauds New Prior Authorization Legislation
News | Radiation Therapy | June 07, 2019
The American Society for Radiation Oncology (ASTRO) released a statement applauding Congress’s introduction of...
IBA Dosimetry Launches myQA iON
News | Quality Assurance (QA) | June 07, 2019
IBA (Ion Beam Applications S.A.) announced the launch of myQA iON at the 2019 Particle Therapy Co-Operative Group (...
Study Identifies MRI-Guided Radiation Therapy as Growing Market Segment
News | Image Guided Radiation Therapy (IGRT) | June 06, 2019
Revenues from the magnetic resonance imaging (MRI)-guided radiation therapy systems market exceeded $220 million in...
RefleXion Opens New Manufacturing Facility for Biology-guided Radiotherapy Platform
News | Radiation Therapy | May 31, 2019
RefleXion Medical recently announced the opening of its new manufacturing facility at its headquarters in Hayward,...
Accuray Radixact

Accuray Radixact

Feature | Radiation Therapy | May 29, 2019 | By Jeff Zagoudis
While radiation therapy as a disciplin
Sponsored Content | Case Study | Radiation Therapy | May 29, 2019
The so-called “Grey Tsunami” of baby boomers using healthcare services isn’t taking the Radiation Medicine Program at
Improved Imaging for Prostate Cancer Could Lead to More Effective Treatment

The picture shows that time series signal is extracted from a series of ultrasound frames for classification. Each patch across a number of frames inside the prostate is classified into either cancerous or normal tissue. The image at the lower right corner shows the overall result for those frames. Image courtesy of Pingkun Yan and researchers from NIH, University of British Columbia and Queens University.

News | Ultrasound Imaging | May 28, 2019
Engineers at Rensselaer Polytechnic Institute are working to improve imaging methods in order to make medicine more...